Clene Inc. Submits Briefing Book to FDA for CNM-Au8 ALS Treatment Approval Process
Clene Inc. and its subsidiary submit a briefing book to the FDA for potential approval of CNM-Au8 as a treatment for ALS, demonstrating progress in the development of new therapeutic options for neurodegenerative diseases.
This news is important as it highlights the efforts of Clene Inc. to seek FDA approval for CNM-Au8 as a treatment for ALS. If successful, this could potentially lead to a new therapeutic option for patients suffering from this debilitating neurodegenerative disease.
